Press Releases
-
Sarepta Therapeutics Applauds Addition of Duchenne Muscular Dystrophy to the U.S. Recommended Uniform Screening Panel (RUSP)
-
Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027
-
Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
Spotlight
The Complexities of Gene Therapy Manufacturing
Learn more about what goes into manufacturing gene therapies and Sarepta’s approach to meeting the challenges inherent in making these transformative therapies a reality for patients with rare diseases.
Highlights
Our FDA-Approved Treatments
Learn more about our FDA-approved treatments.
A Day in The Life at Sarepta
Hear from employees and how our mission drives their work.
